19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
18:02 , Feb 15, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains A chemically modified nuclease-deficient Cas9-based system could help deliver drugs to specific sites in the genome. The system consisted of a nuclease-deficient Cas9 chemically linked to a small molecule or protein drug...
08:00 , Jan 11, 2016 |  BioCentury  |  Emerging Company Profile

Synaptic sound

Decibel Therapeutics Inc. plans to use new mechanistic insights by its academic founders to develop therapies that protect against, restore or repair hearing loss. The company is armed with a $52 million series A round...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Neurotrophin 3 (NTF3)

Neurology INDICATION: Spinal cord injury (SCI) Studies in rats suggest sustained local delivery of NTF3 using NTF3-chitosan could help treat SCI. NTF3-chitosan consists of NTF3 embedded in a 5-mm chitosan tube that allows for slow...
07:00 , Sep 15, 2014 |  BioCentury  |  Emerging Company Profile

Levicept: Modulating NGF

Levicept Ltd. 's p75NTR-Fc could provide the analgesic effect of nerve growth factor inhibitors to treat pain in osteoarthritis without the side effects that have sidelined the class in recent years. This potential made Levicept...
07:00 , May 8, 2014 |  BC Innovations  |  Tools & Techniques

Zapping hearing loss

The most advanced cochlear implants for hearing loss lack frequency resolution and dynamic range, causing recipients to perceive sounds as loud, monotonous and robotic. An Australian team may have solved those problems with a combination...
08:00 , Mar 4, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Neuroendocrine tumors Neurotrophin 3 (NTF3); neurotrophic tyrosine kinase receptor 3 (NTRK3; TrkC) In vitro and in vivo studies suggest that inhibiting NTF3-TrkC signaling could help...